HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L'Oreal “New Markets” Sales Surpass Western Europe In Q1

This article was originally published in The Rose Sheet

Executive Summary

L’Oreal’s sales in Eastern Europe, Asia Pacific, Latin America and Africa/Middle East made up 39.4% of its total cosmetics sales for the first quarter, surpassing Western Europe at 36.8%. The firm’s luxury unit continues to enjoy strong momentum, booking €1.32 billion ($1.73 billion) in sales, up 12.2% from the prior-year period.

You may also be interested in...



L'Oreal's Consumer Brands Drive North America Sales, Share Gains

Maybelline, L’Oreal Paris and Garnier led a 7.9% sales increase on a like-for-like basis in North America in the second fiscal quarter, L’Oreal reports July 26. CEO Jean-Paul Agon tells analysts the firm was the “leader in innovation” in cosmetics in all continents and retail channels.

L’Oreal Luxe, Lancome Turnaround Boost Revenue

Cosmetics Industry Awaits FDA’s Allergen List While Working To Inform GMP Rulemaking

The Independent Beauty Association does not yet have insight into what ingredients will be listed in the US FDA’s proposed rulemaking for cosmetic allergen labeling – due by 29 June – but is optimistic the agency will consult industry when it comes to setting the compliance timeline. Meanwhile, industry stakeholders are pushing for international harmonization in the agency’s cosmetic GMPs rulemaking.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel